OR WAIT null SECS
December 17, 2024
The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia.
December 13, 2024
A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.
December 06, 2024
The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities.
Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.
December 02, 2024
A total of 140 companies are being placed on the Entity List, in an effort to limit China’s effectiveness in the sector.
November 29, 2024
The transaction reaffirms the CDMO’s interest in growth on a global scale.
November 26, 2024
Why well-organized documentation is critical at every stage of the process.
November 25, 2024
The CDMO’s offerings will now feature automated fill-finish.
November 21, 2024
The CDMO's California facility welcomes new production suites, a revamp of its development labs, and more.
November 19, 2024
The CDMO is investing $3.6 million toward boosting its advanced labeling, automated visual inspection, and fill-finish tech.